
Serna Bio
Serna Bio is a YC Winter 2021 (W21) company. Based in Ontario, CA, USA; Remote. Team of 5.
About Serna Bio
Summary
Serna Bio develops small molecules that regulate protein expression by targeting RNA directly, rather than proteins themselves. Its AI-native discovery platform maps druggable RNA structures and screens RNA-small molecule interactions to identify and optimize drug candidates. The platform opens therapeutic targets that conventional protein-focused drug discovery cannot reach, covering protein downregulation, upregulation, and splicing correction.
Go-to-market
Serna Bio advances its own internal pipeline built on the platform, positioning the technology toward pharmaceutical partnerships targeting RNA-driven diseases.
From the Y Combinator listing
Genetic Medicine with Small Molecules
Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities.
Facts
- Healthcare / Healthcare -> Therapeutics
- Ontario, CA, USA; Remote
- 5
- Active
- Early
Founders (1)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works